| Zacks Company Profile for Myriad Genetics, Inc. (MYGN : NSDQ) |
|
|
| |
| • Company Description |
| Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.
Number of Employees: 2,700 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $5.50 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,270,697 shares |
| Shares Outstanding: 92.18 (millions) |
| Market Capitalization: $506.98 (millions) |
| Beta: 1.91 |
| 52 Week High: $29.30 |
| 52 Week Low: $3.81 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
5.97% |
2.00% |
| 12 Week |
-28.01% |
-39.45% |
| Year To Date |
-59.88% |
-62.43% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Paul J. Diaz - Chief Executive Officer; President and Director
S. Louise Phanstiel - Chair of the Board
Scott J. Leffler - Chief Financial Officer
Paul Bisaro - Director
Heiner Dreismann - Director
|
|
Peer Information
Myriad Genetics, Inc. (CORR.)
Myriad Genetics, Inc. (RSPI)
Myriad Genetics, Inc. (CGXP)
Myriad Genetics, Inc. (BGEN)
Myriad Genetics, Inc. (GTBP)
Myriad Genetics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 62855J104
SIC: 2835
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 92.18
Most Recent Split Date: 3.00 (2.00:1)
Beta: 1.91
Market Capitalization: $506.98 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.09 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.39 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 27.47% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
